The estimated Net Worth of Priti Patel is at least 143 千$ dollars as of 31 March 2023. Dr Patel owns over 10,000 units of Neoleukin Therapeutics stock worth over 143,376$ and over the last 4 years he sold NLTX stock worth over 0$.
Dr has made over 3 trades of the Neoleukin Therapeutics stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 10,000 units of NLTX stock worth 34,900$ on 31 March 2023.
The largest trade he's ever made was exercising 35,000 units of Neoleukin Therapeutics stock on 1 February 2023 worth over 122,150$. On average, Dr trades about 7,857 units every 48 days since 2021. As of 31 March 2023 he still owns at least 41,082 units of Neoleukin Therapeutics stock.
You can see the complete history of Dr Patel stock trades at the bottom of the page.
Dr. Priti Patel M.D., M.S. is the Chief Medical Officer at Neoleukin Therapeutics.
Priti's mailing address filed with the SEC is C/O NEOLEUKIN THERAPEUTICS, INC., 188 EAST BLAINE STREET, #450, SEATTLE, WA, 98102.
Over the last 5 years, insiders at Neoleukin Therapeutics have traded over 425,653$ worth of Neoleukin Therapeutics stock and bought 6,490,231 units worth 38,477,971$ . The most active insiders traders include Bros. Advisors Lp667, L.P.B...、Group, Llc Green Jeremy Red...、Bros. Advisors Lp667, L.P.B.... On average, Neoleukin Therapeutics executives and independent directors trade stock every 37 days with the average trade being worth of 593,084$. The most recent stock trade was executed by Bros. Advisors Lp667, L.P.B... on 15 August 2023, trading 2,285,342 units of NLTX stock currently worth 1,462,619$.
Neoleukin Therapeutics, Inc., a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma. The company was formerly known as Aquinox Pharmaceuticals, Inc. and changed its name to Neoleukin Therapeutics, Inc. in August 2019. Neoleukin Therapeutics, Inc. was founded in 2003 and is headquartered in Seattle, Washington.
Neoleukin Therapeutics executives and other stock owners filed with the SEC include: